Evidence map›Paper›PMID 38339125›Full record

ArticleInternational journal of molecular sciences2024

Hematopoietic Prostaglandin D Synthase Is Increased in Mast Cells and Pericytes in Autopsy Myocardial Specimens from Patients with Duchenne Muscular Dystrophy.

Kengo Hamamura, Yuya Yoshida, Kosuke Oyama, Junhao Li, Shimpei Kawano, Kimiko Inoue, Keiko Toyooka, Misaki Yamadera, Naoya Matsunaga, Tsuyoshi Matsumura and 1 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Kengo HamamuraLaboratory of Chemical Pharmacology, Faculty of Pharmaceutical Sciences, Daiichi University of Pharmacy, Fukuoka 815-8511, Japan.ORCID 0000-0001-9146-8554
Yuya YoshidaDepartment of Clinical Pharmacokinetics, Faculty of Pharmaceutical Sciences, Kyushu University, 3-1-1 Maidashi Higashi-ku, Fukuoka 812-8582, Japan.ORCID 0000-0003-2394-9748
Kosuke OyamaDepartment of Pharmaceutics, Faculty of Pharmaceutical Sciences, Kyushu University, 3-1-1 Maidashi Higashi-ku, Fukuoka 812-8582, Japan.ORCID 0009-0004-7821-5236
Junhao LiDepartment of Clinical Pharmacokinetics, Faculty of Pharmaceutical Sciences, Kyushu University, 3-1-1 Maidashi Higashi-ku, Fukuoka 812-8582, Japan.
Shimpei KawanoDepartment of Clinical Pharmacokinetics, Faculty of Pharmaceutical Sciences, Kyushu University, 3-1-1 Maidashi Higashi-ku, Fukuoka 812-8582, Japan.
Kimiko InoueDepartment of Neurology and Rehabilitation Medicine, National Hospital Organization Osaka Toneyama Medical Center, Toneyama 5-1-1, Toyonaka 560-8552, Japan.
Keiko ToyookaDepartment of Neurology, National Hospital Organization Osaka Toneyama Medical Center, Toneyama 5-1-1, Toyonaka 560-8552, Japan.
Misaki YamaderaDepartment of Clinical Research, National Hospital Organization Osaka Toneyama Medical Center, Toneyama 5-1-1, Toyonaka 560-8552, Japan.ORCID 0000-0002-6860-6338
Naoya MatsunagaDepartment of Clinical Pharmacokinetics, Faculty of Pharmaceutical Sciences, Kyushu University, 3-1-1 Maidashi Higashi-ku, Fukuoka 812-8582, Japan.
Tsuyoshi MatsumuraDepartment of Neurology, National Hospital Organization Osaka Toneyama Medical Center, Toneyama 5-1-1, Toyonaka 560-8552, Japan.ORCID 0000-0001-6241-3626
Kosuke AritakeLaboratory of Chemical Pharmacology, Faculty of Pharmaceutical Sciences, Daiichi University of Pharmacy, Fukuoka 815-8511, Japan.
Kyushu University · JPToneyama National Hospital · JPDaiichi University of Pharmacy · JP

Funding

Grant-in-Aid for Scientific Research C from Japan for the Promotion of Science 21K11613Japan Agency for Medical Research and Development JP22wm042501
6 · The paper itself

Abstract

The leading cause of death for patients with Duchenne muscular dystrophy (DMD), a progressive muscle disease, is heart failure. Prostaglandin (PG) D

Indexed as

CardiomyopathiesIntramolecular OxidoreductasesLipocalinsMuscular Dystrophy, DuchenneAnimalsDisease Models, AnimalHumansMast CellsMiceMice, Inbred mdxMuscle, SkeletalMyocardiumPericytesHPGDS protein, humanIntramolecular OxidoreductasesLipocalinsprostaglandin R2 D-isomeraseDuchenne muscular dystrophyhematopoietic prostaglandin D synthasemast cellmyeloid cellpericyteprostaglandin D2

Identifiers

PMID38339125
PMCPMC10855661
OpenAlexW4391533958

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.